Osteoclastogenesis is a tightly regulated biological process, and deregulation can lead to severe bone disorders such as osteoporosis. The regulation of osteoclastic signaling is incompletely understood, but ubiquitination of TNF receptor-associated factor 6 (TRAF6) has recently been shown to be important in mediating this process. We therefore investigated the role of the recently identified deubiquitinating enzyme CYLD in osteoclastogenesis and found that mice with a genetic deficiency of CYLD had aberrant osteoclast differentiation and developed severe osteoporosis. Cultured osteoclast precursors derived from CYLD-deficient mice were hyperresponsive to RANKL-induced differentiation and produced more and larger osteoclasts than did controls upon stimulation. We assessed the expression pattern of CYLD and found that it was drastically upregulated during RANKL-induced differentiation of preosteoclasts. Furthermore, CYLD negatively regulated RANK signaling by inhibiting TRAF6 ubiquitination and activation of downstream signaling events. Interestingly, we found that CYLD interacted physically with the signaling adaptor p62 and thereby was recruited to TRAF6. These findings establish CYLD as a crucial negative regulator of osteoclastogenesis and suggest its involvement in the p62/TRAF6 signaling axis.
Introduction
Normal bone physiology is regulated by the harmonic actions of osteoblasts and osteoclasts (OCs), cells that mediate bone formation and bone resorption, respectively (1) . OCs are multinucleated cells that are derived from macrophage precursors. OC differentiation is induced by RANKL in the presence of the macrophage growth factor M-CSF (2, 3) . Binding of RANKL to its receptor, RANK, stimulates receptor trimerization and recruitment of signaling adaptors, most importantly TNF receptor-associated factor 6 (TRAF6) (4) . TRAF6 transduces the RANK-mediated signal by initiating a number of downstream signaling pathways, including those that activate the transcription factors NF-κB and activator protein 1 (AP-1) (4, 5) . These transcription factors in turn induce the expression of a master osteoclastogenic regulator, nuclear factor of activated T cells c1 (NFATc1), and trigger a cascade of gene expression events required for OC differentiation (3, 5, 6) . Genetic deficiencies in TRAF6 or its downstream signaling factors attenuate OC differentiation and bone resorption, a condition known as osteopetrosis (3, 7) . On the other hand, excessive production or activation of OCs can lead to uncontrolled bone resorption or osteoporosis. Thus, a fundamental understanding of RANK signaling is important for rational design of therapeutic approaches for the treatment of bone disorders.
Recent studies suggest that ubiquitination of TRAF6 is an important mechanism mediating its signaling functions (8) (9) (10) .
Lysine 63-linked polyubiquitin chains facilitate the association of TRAF6 with target signaling factors, such as IκB kinase (IKK), a multisubunit enzyme mediating activation of NF-κB (11) . The regulatory subunit of IKK, IKKγ (also known as NEMO), has intrinsic ubiquitin-binding activity and is thought to recruit the IKK catalytic subunits, IKKα and IKKβ, to ubiquitinated upstream regulators (12, 13) . How the ubiquitination and signaling function of TRAF6 are regulated under physiological conditions, particularly during osteoclastogenesis, is incompletely understood. Nevertheless, an adaptor protein, p62 (also known as sequestosome 1) , has been shown to physically associate with TRAF6 and play both positive and negative roles in RANK signaling. Complete loss of p62 attenuates RANK signaling and osteoclastogenesis (14) . On the other hand, mutations of p62 that disrupt its C-terminal ubiquitin association (UBA) domain cause aberrant RANK signaling and hyperproduction of OCs (3, (15) (16) (17) (18) . Such genetic alterations of p62 are etiologically associated with development of Paget disease of bone (PDB), a severe bone disorder characterized by formation of giant OCs, excessive bone resorption, and irregular bone formation (15, 19, 20) . The positive signaling role of p62 appears to involve recruitment of atypical PKCs to TRAF6, which contributes to IKK activation by RANK (14) . Although how p62 negatively regulates RANK signaling is unclear, one implication is that p62 may be involved in interaction with negative regulators.
An emerging family of signaling regulators involved in diverse biological processes are deubiquitinating enzymes (DUBs), which digest ubiquitin chains and reverse the process of protein ubiquitination (21) . One DUB, CYLD, has been implicated as an important regulator of immune response and oncogenesis (22) (23) (24) (25) (26) (27) (28) . The signaling function of CYLD appears to be cell type specific. Thus, CYLD negatively regulates the activation of IKK and JNK in lymphocytes but has no obvious role in regulating these signal-ing events in macrophages (22) (23) (24) . In the present study, we show that the expression level of CYLD is extremely low in macrophages but is markedly upregulated under conditions of RANKL-induced osteoclastogenesis. We provide genetic evidence that CYLD is a crucial negative regulator of RANK signaling in preosteoclasts. The loss of CYLD in mice causes production of enlarged and hypernucleated OCs, associated with severe osteoporosis. Interestingly, the adaptor protein p62 physically interacts with CYLD and promotes the binding of CYLD to TRAF6, and this novel molecular interplay requires the C-terminal region of p62. These findings establish CYLD as what we believe to be the first DUB that regulates osteoclastogenesis and suggest a potential mechanism mediating the negative signaling function of p62.
Results

Cyld-knockout mice develop osteoporosis.
To investigate the physiological functions of CYLD, we generated Cyld-knockout mice (22) . During the preparation of bone marrow cells, we noticed that the femurs of Cyld-knockout (Cyld -/-) mice appeared to be more fragile than those of wild-type mice. This finding prompted us to compare the bone mass and structure of Cyld -/-and wild-type (Cyld +/+ ) mice.
Femurs of Cyld +/+ and Cyld -/-mice were subjected to microcomputed tomography (microCT) analyses. The Cyld -/-mice exhibited severe loss of trabecular bone, as shown in representative images of 3D microCT reconstruction ( Figure 1A) . Consistently, the volume of trabecular bone per unit of metaphysis (BV/TV) was reduced by almost half in the Cyld -/-mice ( Figure 1B) . The mutant animals also displayed obvious abnormalities in several other parameters of trabecular bone architecture, including decreased trabecular number and trabecular thickness (Tb. Th), but increased trabecular separation, which together suggested a reduced and more separated trabecular bone network. Structure model index is scored from 0 to 3 for indication of increased fragility. Compared with wild-type femurs, the Cyld -/-femurs had dramatically higher SMI numbers and lower degree of anisotropy and connectivity density, indicating more fragile bone in the mutant animals ( Figure 1B) . In agreement with the trabecular bone data, analysis of the cortical bone at the midshaft level revealed a moderate but significant decrease in cortical bone thickness ( Figure 1C , Tb. Th). The total volume (TV) of cortical bone and the volume of bone fraction (BV) were also reduced. However, the proportion of bone (BV/TV) remained the same in wild-type and Cyld -/-femurs, indicating decreased diameter of Cyld -/-femurs but not defect in osteoblast function. These results suggest that the loss of CYLD in mice leads to osteoporosis.
Cyld -/-mice exhibit OC abnormalities. To address the mechanism by which CYLD regulates bone density, we performed histological analyses of femurs from Cyld +/+ and Cyld -/-mice. Consistent with the microCT results, H&E staining of femoral sections revealed a severe reduction in trabecular bone in Cyld -/-mice ( Figure 2A) . Moreover, the Cyld -/-trabecular bone contained increased OC activity, as revealed by positive staining with tartrate-resistant acid phosphatase (TRAP) ( Figure 2B ). Additionally, the OCs from Cyld -/-mice were markedly enlarged in size ( Figure 2C ). On the other hand, bone nodule assays to test the ability of osteoblasts to form mineralized bone in vitro did not show obvious difference between the Cyld -/-and wild-type mice ( Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/JCI34257DS1). Furthermore, the Cyld -/-mice only had a weak increase in serum concentration of osteocalcin, an indicator of osteoblast activity (Supplemental Figure 1B) . Thus, as seen with mice expressing a p62 mutant (18) , the Cyld -/-mice have abnormalities predominantly in OCs, leading to osteoporosis.
CYLD negatively regulates osteoclastogenesis. The OC abnormalities in Cyld -/-mice led us to examine the role of CYLD in regulating OC differentiation. Bone marrow-derived macrophages (BMDMs) were cultured in M-CSF growth medium in either the absence or presence of RANKL. As expected, RANKL induced the generation of TRAPpositive OCs at a concentration of 100 ng/ml ( Figure 3A ). Remarkably, the same concentration of RANKL induced a drastically higher number of OCs in the Cyld -/-BMDMs ( Figure 3A) . The Cyld -/-OCs were also notably larger ( Figure 3A ) and contained substantially more nuclei than the control OCs ( Figure 3B ). A dose-response assay revealed that loss of CYLD also rendered the cells responsive to lower doses of RANKL ( Figure 3C ). These results were not due to alteration in the surface expression of RANK (Supplemental Figure 2) . The level of M-CSF receptor (M-CSFR) was also similar in the wild-type and Cyld -/-cells (Supplemental Figure 2) . Consistent with these results, overexpression of CYLD in wild-type OC precursor cells strongly inhibited the osteoclastogenesis (Supplemental Figure 3) .
We next performed real-time PCR to examine the effect of Cyld deficiency on the induction of osteoclastogenic markers, including the early markers TRAP and cathepsin K and the late marker calcitonin receptor. Following RANKL stimulation, the expression of TRAP and cathepsin K was increased within 1-2 days, whereas the induction of calcitonin receptor occurred at 2-3 days ( Figure  3D ). Importantly, induction of both the early and late osteoclastogenic markers was greatly potentiated in Cyld -/-cells ( Figure 3D ). Together, these results suggest a crucial role for CYLD in negatively regulating osteoclastogenesis.
CYLD negatively regulates RANK signaling in preosteoclasts. To elucidate the molecular mechanism by which CYLD negatively regulates osteoclastogenesis, we examined the effect of Cyld deficiency on RANKL-stimulated signaling events. Stimulation of wild-type BMDMs with RANKL resulted in rapid activation of MAPKs, including ERK, JNK, and p38 ( Figure 4A ) as well as NF-κB ( Figure 4B ). The Cyld deficiency had no obvious effect on the early activation of MAPKs ( Figure 4A ). Similarly, during the initial phase of RANKL stimulation in BMDMs, the loss of CYLD did not substantially affect the activation of NF-κB ( Figure 4B ). Another transcription factor, AP-1, was not detected under the short-term stimulation conditions (data not shown). Thus, CYLD is not involved in regulation of the initial phase of RANK signaling in BMDMs.
We next examined the role of CYLD in RANK signaling in developing OCs, hereafter referred to preosteoclasts. Active NF-κB and AP-1 were detected in the nuclei of preosteoclasts exposed to RANKL for 2 days ( Figure 4C ). Interestingly, the activity of both NF-κB and AP-1 was markedly enhanced in Cyld -/-cells. Recent studies suggest that OC development involves induction of NFATc1, a master regulator of osteoclastogenesis (5, 29) . Since NF-κB and AP-1 have been implicated in the induction of NFATc1, we examined whether the loss of CYLD also promoted NFATc1 induction. Indeed, substantially higher levels of NFATc1 were induced by RANKL in Cyld -/-cells than in the control cells ( Figure 4D ). On the other hand, the loss of CYLD did not affect the induction of TRAF6 or constitutive expression of the protein kinase Tak1 ( Figure 4D ). These results suggest that CYLD regulates the sustained activation of NF-κB and AP-1 and induction of NFATc1 in preosteoclasts, which provides a molecular insight into the role of CYLD in regulating osteoclastogenesis.
Induction of CYLD expression under conditions of OC differentiation. Because of the distinct roles of CYLD in BMDMs and preosteoclasts, we examined its expression pattern under conditions of RANKL-induced OC differentiation. Consistent with its dispensable role during the early phase of RANK signaling, the level of CYLD was extremely low in BMDMs ( Figure 5A ). Interestingly, CYLD expression was markedly increased after 1 day of RANKL stimulation and further upregulated after prolonged stimulation ( Figure 5A and data not shown). The RANKL-induced upregulation of CYLD protein was associated with induction of Cyld mRNA, as determined by parallel real-time PCR assays (Figure 5B ). This pattern of CYLD expression provides a good explanation for its specific signaling function in preosteoclasts.
Since RANKL stimulates rapid activation of both canonical NF-κB and MAPKs in BMDMs, the delayed induction of CYLD expression suggested the requirement of additional regulators. As an initial approach to address this issue, we examined whether CYLD expression is also induced by other macrophage inducers, including the bacterial endotoxin LPS and the proinflammatory cytokine TNF-α. In contrast to RANKL, neither TNF-α nor LPS substantially increased the expression of CYLD ( Figure 5C ). On the other hand, LPS potently increased the expression of a known proinflammatory mediator, iNOS, and both TNF-α and LPS induced the expression of the Nfkb2 gene product p100 ( Figure 5C ). Thus, the induction of CYLD appeared to be specifically mediated by the OC inducer RANKL.
An important feature of RANKL-stimulated signaling is the induction of noncanonical NF-κB (30), a process that is regulated by NF-κB-inducing kinase (NIK) and involves processing of the NF-κB2 precursor protein p100 to generate p52 (31) . To examine the involvement of noncanonical NF-κB in CYLD induction, we examined RANKL-stimulated expression of CYLD in Nik -/-and control BMDMs. As expected, RANKL stimulated the processing of p100 (generation of p52) in wild-type but not Nik -/-cells ( Figure 5D ). Interestingly, the RANKL-induced expression of CYLD was severely attenuated, although not completely blocked, in Nik -/-cells. Thus, optimal induction of CYLD by RANKL requires the noncanonical NF-κB signaling pathway, which may function in cooperation with the canonical NF-κB and other signaling pathways.
CYLD is assembled into the TRAF6 complex and negatively regulates TRAF6 ubiquitination in preosteoclasts. TRAF6 is a master signaling molecule controlling multiple downstream pathways induced by RANKL. Ubiquitination of TRAF6 plays an important role in its signaling function, including the regulation of osteoclastogenesis (8) (9) (10) . The finding that CYLD negatively regulates RANK signaling and osteoclastogenesis prompted us to examine whether the loss of CYLD altered ubiquitination of TRAF6 in preosteoclasts. As expected, polyubiquitinated TRAF6 was detected in RANKLinduced preosteoclasts ( Figure 6A ). Importantly, substantially more ubiquitinated TRAF6 was accumulated in Cyld -/-cells (Figure 6A) . Moreover, the TRAF6 ubiquitination in Cyld -/-cells was more persistent than in Cyld +/+ cells, as revealed when the cells were chased in RANKL-free media ( Figure 6A, lanes 5 and 6) . Consistent with these results, transfected CYLD potently inhibited RANK-induced TRAF6 ubiquitination (Supplemental Figure 4) . Thus, CYLD plays a nonredundant role in suppressing the ubiquitination of TRAF6 during RANKL-induced OC differentiation, a finding that provides an insight into the molecular mechanism by which CYLD regulates osteoclastogenesis.
We next examined the physical association between CYLD and TRAF6. The expression level of both CYLD and TRAF6 was upregulated in RANKL-induced preosteoclasts ( Figure 6B , middle and bottom panels). Moreover, TRAF6 and CYLD were coprecipitated ( Figure 6B, top panel) , indicating their presence in the same complex. Together, these results emphasize a physiological role of CYLD in negatively regulating TRAF6 ubiquitination mediated by RANKL.
p62 physically interacts with CYLD and promotes the CYLD/TRAF6 association. Prior studies have identified p62 as a component of the TRAF6 complex during osteoclastogenesis (14) . Like CYLD, p62 is markedly induced during RANKL-stimulated OC differentiation ( Figure 6C and ref. 14) . Since p62 is known as an adaptor of TRAF6, we examined whether CYLD was physically associated with p62. Indeed, a stable complex of p62 and CYLD was readily identified from preosteoclasts by coimmunoprecipitation assays ( Figure 6C ). The p62/CYLD interaction was also demonstrated using transfected 293 cells ( Figure 6D ). Interestingly, a p62 mutant lacking its C-terminal UBA domain (p62ΔUBA) was largely defective in CYLD binding ( Figure 6D ). This phenotype of p62ΔUBA was not due to the variation in its expression, since this mutant was expressed at even higher levels than the wild-type p62.
Figure 4
RANK signaling is normal in BMDMs but aberrant in preosteoclasts in the absence of CYLD. (A) BMDMs were cultured in M-CSFcontaining medium and stimulated with GST-RANKL (100 ng/ml) for the indicated times and subjected to IB assays using phosphospecific (P-) or regular antibodies against the indicated MAPKs or tubulin. (B) BMDMs were stimulated with GST-RANKL for the indicated times as in A, and the nuclear NF-κB DNA binding activity was detected by EMSA. (C) BMDMs were cultured for 2 days in M-CSF medium lacking (represented by 0) or containing the indicated amounts of GST-RANKL. Nuclear extracts were subjected to EMSA to detect the activation of NF-κB or AP-1. An IB of lamin B was included as a loading control. (D) BMDMs were cultured in M-CSF medium for 2 days in the absence of RANKL (NT) or for the indicated days in the presence of RANKL. Total cell lysates were subjected to IB to detect the indicated proteins.
The strong interaction of p62 with CYLD led us to examine whether p62 facilitates the assembly of CYLD into the TRAF6 complex. We found that in 293 cells, endogenous TRAF6 did not appreciably associate with CYLD ( Figure 6E , top panel, lane 2), a finding that was consistent with a previous report (32) . Remarkably, however, expression of p62 in the cells induced the complex formation between CYLD and TRAF6 ( Figure 6E , top panel, lane 3, and Supplemental Figure 5) . Furthermore, this function of p62 was correlated with its CYLD-binding activity, since it was not seen with the p62ΔUBA mutant (lane 4). Thus, p62 appears to function as an adaptor recruiting CYLD to TRAF6, thus providing a molecular insight into the negative function of p62 in osteoclastogenesis. On the other hand, the association of p62 with TRAF6 was not affected by CYLD (Supplemental Figure 6) . CYLD was also not involved in RANK-mediated activation of PKCζ (Supplemental Figure 6) , which is thought to involve the positive signaling function of p62. These findings suggest that CYLD may specifically mediate the negative signaling function of p62 by deubiquitinating TRAF6.
Discussion
Osteoclastogenesis is a tightly controlled biological process that involves both positive and negative regulation. Compared with the positive players, the negative regulators of this process are relatively less well understood. Prior studies have identified the suppressive role of SHIP-1 and IRAK-M in OC formation. Both proteins are abundantly expressed in macrophages, the OC precursors, and have inhibitory roles in innate immune signaling (33, 34) . SHIP-1 controls osteoclastogenesis by targeting M-CSFR signaling, while IRAK-M acts by inhibiting the IL-1 receptor pathway (35) (36) (37) . Our present study suggests that CYLD, unlike SHIP-1 or IRAK-M, functions as a specific negative regulator of OC development by suppressing RANK signaling.
We have previously shown that loss of CYLD in macrophages has no obvious effect on the signaling events mediated by innate immune stimuli, such as TNF-α and LPS (22, 24) . Similarly, we have found in the present study that CYLD does not regulate RANKLstimulated initial signaling in BMDMs. In sharp contrast, CYLD has a crucial role in controlling RANKL-stimulated signaling in preosteoclasts. This functional diversity of CYLD is likely due to its differential expression. The level of CYLD is very low in BMDMs, but it is drastically upregulated in preosteoclasts. Interestingly, the induction of CYLD expression is specific for RANKL signal, as it is not seen with the proinflammatory stimuli TNF-α and LPS, which potentially explains the functional specificity of CYLD in RANK signaling. Although how RANKL specifically induces the expression of CYLD is incompletely understood, our data suggest the requirement of a noncanonical NF-κB signaling pathway. Thus, as depicted in Figure 7 , we believe Cyld to be a novel target gene of RANK signaling that is involved in the feedback inhibition.
The expression pattern of CYLD is reminiscent of that of p62 (14) , a signaling adaptor with positive and negative roles in regulating osteoclastogenesis. p62 physically associates with TRAF6 and appears to promote RANK signaling by recruiting atypical PKCs to TRAF6 (14) . Under overexpression conditions, p62 also induces the self-ubiquitination activity of TRAF6, although the physiological relevance remains unclear (38) . How p62 negatively regulates RANK signaling has remained poorly understood, although this function of p62 is known to require its C-terminal region (3, (15) (16) (17) (18) . Our present study shows that p62 physically interacts with CYLD and promotes the binding of CYLD to TRAF6. CYLD is assembled into the TRAF6 complex and plays an essential role in preventing excessive ubiquitination of TRAF6 in preosteoclasts. Moreover, the C-terminal region of p62 is essential for its adaptor function to promote CYLD/TRAF6 interaction. These findings suggest an intriguing molecular interplay between p62 and CYLD and shed light on how p62 negatively regulates RANK signaling (Figure 7) .
A recent study demonstrates that transgenic mice expressing a mutated form of p62 develop osteoporosis, although the p62 mutation is insufficient to cause the full PDB phenotype (18) . In particular, the p62 mutation causes abnormal osteoclastogenesis but does not enhance osteoblast numbers and activity, as seen in PDB. These findings suggest that p62 mutations may predispose individuals to, but be insufficient for, the development of PDB. Our data indicate that CYLD may mediate an important part of the negative signaling functions of p62. As seen with the p62-mutant transgenic mice, Cyld -/-mice spontaneously develop osteoporosis, although they do not show significant abnormalities in osteoblast development and function. Our in vitro studies
Figure 5
Induction of CYLD expression by RANKL but not by LPS or TNF-α. (A) Wild-type BMDMs were cultured in M-CSF-containing medium in the absence of RANKL (NT) or for the indicated times in the presence of GST-RANKL (100 ng/ml). Total cell lysates were subjected to IB to detect CYLD and tubulin. (B) Real-time RT-PCR was performed using RNA isolated from cells as described in A to determine the relative expression of Cyld mRNA. (C) Wild-type BMDMs were cultured in M-CSF medium for 1 day in either the absence (NT) or presence of the indicated inducers. Total cell lysates were subjected to IB to detect the indicated proteins. (D) BMDMs prepared from Nik-knockout (NIK-/-) and control (NIK+/+) mice were cultured for 1 day in the absence (-) or presence (+) of GST-RANKL (100 ng/ml) followed by IB to detect the expression of CYLD (top panel) or processing of p100 (middle 2 panels). A tubulin IB was used as a loading control.
Figure 6
CYLD targets TRAF6, which is promoted by p62. (A) Wild-type and Cyld -/-BMDMs were cultured for 2 days in M-CSF medium in either the absence (-) or presence (+) of GST-RANKL. TRAF6 was isolated by IP followed by IB to detect ubiquitin-conjugated TRAF6 (upper panel) or unmodified TRAF6 (lower panel). In lanes 5 and 6, the RANKL-treated cells were chased in RANKL-free media overnight before the TRAF6 ubiquitination assay. (B) Wild-type BMDMs were cultured for 2 days in M-CSF medium in the absence or presence of GST-RANKL. TRAF6 was isolated by IP followed by detection of the associated CYLD by IB (top panel). The lysates were subjected to IB to monitor the expression of CYLD and TRAF6 (middle and bottom panels). (C) Wild-type BMDMs were cultured for 2 days in M-CSF medium in the absence or presence of GST-RANKL. CYLD was isolated by IP followed by detection of the associated p62 by IB (top panel). The cell lysates were subjected to IB to monitor the expression of CYLD and p62 (middle and bottom panels). (D) 293 cells were transfected with CYLD along with vector control (V), wild-type p62, or p62ΔUBA. CYLD was isolated by IP, and its associated p62 was detected by IB (top panel). Protein expression in cell lysates was monitored by direct IB (middle and bottom panels). (E) 293T cells were transfected with either an empty vector or expression vectors encoding wild-type p62 or p62ΔUBA. Lanes 2-4 were also transfected with CYLD. Endogenous TRAF6 was isolated by IP followed by IB to detect the associated CYLD or the precipitated TRAF6 (top 2 panels). The cell lysates were subjected to IB to detect the expression of CYLD, EGFP-tagged p62 proteins, and TRAF6 (bottom 3 panels).
Figure 7
A model of CYLD function in RANK signaling. Engagement of RANK by RANKL induces TRAF6 ubiquitination (Ub) and activation of downstream signaling molecules, leading to induction of genes involved in osteoclastogenesis. The RANK signaling also results in upregulation of CYLD as well as p62. CYLD targets TRAF6 via the assistance of p62, thereby negatively regulating TRAF6 ubiquitination and RANK signaling.
